Metabolic Connections to Vision Loss: A Learner’s Guide to Age-Related Ocular Diseases

1. Introduction: The Eye-Metabolism Connection

When considering human vision, it is easy to view the eye as an isolated optical instrument operating independently of the rest of the body. However, modern medical physiology reveals that ocular health is deeply connected to whole-body metabolic health. Systemic conditions such as obesity, type 2 diabetes mellitus (T2DM), and liver dysfunction continuously communicate with ocular tissues through vascular and biochemical pathways. When systemic metabolism deteriorates, the delicate structures of the eye are often among the first to suffer silent, progressive damage. Understanding how body-wide metabolism influences visual pathways provides crucial insights into non-invasive strategies for preventing global vision loss.

The eye is not an isolated island; it is a mirror reflecting systemic metabolic health.

Rather than viewing eye care solely through localized optical treatments, recognizing the metabolic ties to ocular degeneration enables a broader, systemic approach to preserving sight. To understand how systemic metabolic dysfunction impairs vision, we must first examine the specific anatomical structures and pathological changes involved in the four major age-related ocular diseases.

2. Fundamental Breakdown of Four Major Age-Related Ocular Diseases

Age-related eye conditions are leading causes of visual impairment and blindness worldwide. To navigate these pathologies, students must first understand three critical anatomical structures that act as functional anchors within the eye:

• Retinal Pigment Epithelium (RPE): The single layer of pigmented cells situated beneath the sensory retina that nourishes photoreceptors, transports nutrients, and clears metabolic waste.
• Bruch’s Membrane: The thin, extracellular matrix layer positioned directly between the RPE and the underlying blood-rich choroid.
• Trabecular Meshwork: The sponge-like tissue ring located in the anterior chamber angle of the eye that drains aqueous humor to regulate internal eye pressure.

When metabolic stress disrupts these structural anchors, four primary age-related ocular diseases develop:

• Diabetic Retinopathy (DR): A microvascular complication of diabetes presenting in two primary stages: Non-Proliferative Diabetic Retinopathy (NPDR), characterized by microaneurysms, intraretinal hemorrhages, and vascular leakage; and Proliferative Diabetic Retinopathy (PDR), an advanced stage marked by pathological neovascularization (growth of fragile new blood vessels), vitreous hemorrhage, and ocular fibrosis.
• Age-Related Macular Degeneration (AMD): A neurodegenerative condition targeting the macula and RPE. Early stages are defined by the accumulation of drusen (extracellular lipid and protein deposits beneath the RPE on Bruch's membrane). Late stages progress either to geographic atrophy ("dry" AMD, involving localized cell death of the RPE and photoreceptors) or choroidal neovascularization ("wet" AMD, involving abnormal blood vessel growth beneath the retina).
• Cataract: A condition characterized by the progressive opacification (clouding) of the natural crystalline lens of the eye, which scatters incoming light and prevents clear image focus on the retina. Common clinical subtypes include nuclear, cortical, and posterior subcapsular cataracts.
• Glaucoma: A group of neurodegenerative optic neuropathies characterized by the progressive death of Retinal Ganglion Cells (RGCs) and structural cupping of the optic nerve head. It is frequently driven by heightened fluid outflow resistance within the trabecular meshwork, elevating Intraocular Pressure (IOP) and causing irreversible visual field loss.

Ocular Disease	Primary Target Structure	Key Pathological Features	Primary Impact on Visual Function
Diabetic Retinopathy (DR)	Retina & Retinal Microvasculature	Microaneurysms, vascular leakage (NPDR); Neovascularization, macular edema, and vitreous fibrosis (PDR)	Progressive visual blur, central vision loss, floating spots, and severe risk of legal blindness
Age-Related Macular Degeneration (AMD)	Macula, Retinal Pigment Epithelium (RPE), Bruch's Membrane	Drusen accumulation (early stage); Geographic atrophy or choroidal neovascularization (late stage)	Loss of fine central vision, visual distortion (metamorphopsia), and central blind spots
Cataract	Crystalline Lens	Opacification and protein aggregation within the lens (nuclear, cortical, or posterior subcapsular)	Blurred or dimmed vision, light sensitivity, glare, and loss of color contrast
Glaucoma	Optic Nerve Head, Retinal Ganglion Cells (RGCs), Trabecular Meshwork	Increased aqueous humor outflow resistance, elevated Intraocular Pressure (IOP), and RGC apoptosis	Progressive loss of peripheral vision ("tunnel vision"), optic nerve cupping, and eventual blindness

While these diseases target distinct ocular structures, they are largely propelled by shared systemic drivers, including visceral adiposity, steatotic liver dysfunction, and chronic cellular stress pathways.

3. Systemic Drivers & Biological Stress Pathways

3.1 Abdominal/Visceral Adiposity vs. General BMI (The "Obesity Paradox")

Body Mass Index (BMI) has long served as a standard clinical screening tool for weight-related risks. However, medical physiology demonstrates that BMI is a flawed metric for assessing ocular disease risk. Because BMI merely measures total body weight relative to height, it fails to differentiate between lean muscle and adipose mass, nor does it identify where body fat is stored.

This limitation explains the "Obesity Paradox" observed in epidemiological studies, where individuals classified as normal weight or underweight by BMI sometimes exhibit higher rates of Diabetic Retinopathy or Primary Open-Angle Glaucoma (POAG) than individuals classified as obese.

  +-----------------------------------------------------------------------+
  |                           THE BMI PARADOX                             |
  | Total weight divided by height squared fails to measure fat location  |
  +----------------------------------+------------------------------------+
                                     |
            +------------------------+------------------------+
            |                                                 |
            v                                                 v
  +-----------------------------------+   +-----------------------------------+
  |     GENERAL / SUBCUTANEOUS FAT    |   |     VISCERAL / ABDOMINAL FAT      |
  |  • Relatively stable storage      |   |  • Highly metabolically active    |
  |  • Weak correlation with eye loss |   |  • Secretes pro-inflammatory factors|
  |  • Poor predictor of early AMD    |   |  • Drives early drusen & ROS      |
  +-----------------------------------+   +-----------------------------------+

Recent epidemiological findings (such as Xu & Wu, 2025) clarify that visceral adiposity—the metabolically active deep fat surrounding internal organs—serves as a far superior predictor of early ocular pathology compared to total BMI. Key anthropometric indices designed to isolate visceral and central obesity include:

• Waist-to-Height Ratio (WtHR)
• Body Roundness Index (BRI)
• Circularity Index (CI)
• Weight-Adjusted Waist Circumference Index (WWI)

Empirical Insights into Visceral Adiposity and AMD

Advanced epidemiological modeling reveals three crucial nuances regarding these central adiposity indices:

1. Early vs. Late AMD Stage Specificity: Elevated WtHR, BRI, CI, and WWI are significantly associated with early AMD (drusen accumulation, low-grade inflammatory signaling, and RPE pigmentary changes). However, these indices do not significantly correlate with late AMD. In late AMD, irreversible structural destruction (massive geographic atrophy or choroidal neovascularization) creates severe local pathological changes that mask the baseline impact of body fat distribution.
2. Linear vs. Non-Linear Modeling: The Circularity Index (CI) exhibits a direct linear positive relationship with early AMD risk across its entire range. In contrast, WtHR, BRI, and WWI display non-linear positive relationships that plateau at specific biological inflection points (inflection threshold values: WtHR = 0.535, BRI = 4.045, WWI = 12.065), suggesting a biological saturation threshold for metabolic stress in retinal tissue.
3. Critical Effect Modifiers: The positive correlation between central adiposity indices and early AMD is markedly exacerbated by heavy alcohol consumption (P interaction< 0.02). Furthermore, WWI and CI demonstrate significantly stronger associations with AMD in females (P interaction< 0.02), whereas WtHR exhibits a stronger association in non-smokers (P interaction = 0.04).

Biomechanical Mechanism of the Glaucoma Obesity Paradox

The "Obesity Paradox" in glaucoma presents a unique biomechanical phenomenon. While lower BMI / underweight status increases POAG risk, higher BMI often demonstrates a reverse J-shaped protective trend against optic nerve damage. Physiological research reveals that elevated body mass increases retrobulbar Cerebrospinal Fluid (CSF) pressure within the optic nerve subarachnoid space. This heightened CSF pressure acts as a physical counter-pressure behind the eye, balancing elevated Intraocular Pressure (IOP) across the lamina cribrosa and reducing physical shearing forces on Retinal Ganglion Cell axons.

3.2 Liver-Eye Axis (MASLD/NAFLD)

The liver is the principal coordinator of systemic lipid and glucose metabolism. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), historically termed Nonalcoholic Fatty Liver Disease (NAFLD), is a multisystem disorder characterized by abnormal fat accumulation in hepatocytes.

The liver communicates directly with the eye through systemic blood circulation. However, clinical meta-analyses demonstrate a vital physiological distinction between Type 1 and Type 2 Diabetes regarding Retinopathy:

• Type 1 Diabetes Mellitus (T1DM): Simple hepatic steatosis (MASLD/NAFLD) is directly and independently associated with a significantly heightened risk of Diabetic Retinopathy (OR = 2.35).
• Type 2 Diabetes Mellitus (T2DM): Simple hepatic steatosis alone is not an independent risk factor for DR. Instead, DR risk in T2DM correlates specifically with advanced hepatic fibrosis, measured via non-invasive scoring systems such as the Fibrosis-4 (FIB-4) index or the NAFLD Fibrosis Score (NFS).

Beyond retinopathy, advanced liver fibrosis drives systemic vascular damage resulting in retinal atherosclerosis(arteriovenous nicking and arterial narrowing) and a linear increase in cataract formation corresponding to fibrosis severity.

3.3 The Six Core Cellular Stress Mechanisms

Visceral obesity and steatotic liver disease generate six shared cellular stress pathways that degrade ocular tissues:

• Chronic Low-Grade Inflammation: Sustained secretion of systemic pro-inflammatory cytokines damages fragile retinal capillary beds and disrupts RPE barrier function.
• Oxidative Stress & Reactive Oxygen Species (ROS): Uncontrolled ROS generation exceeds intraocular antioxidant defenses, causing lipid peroxidation in the crystalline lens and trabecular meshwork.
• Insulin Resistance (IR): Suppresses physiological glucose uptake in high-energy retinal cells, leading to cellular starvation and microvascular damage.
• Vascular Dysfunction & Neovascularization: Endothelial damage causes microvascular occlusions and localized hypoxia, triggering excessive Vascular Endothelial Growth Factor (VEGF) release that creates fragile, leaky blood vessels.
• Impaired Autophagy: Disruption of normal lysosomal clear-up mechanisms allows toxic protein aggregates and damaged organelles to accumulate in the RPE, promoting drusen growth in AMD.
• Ocular Fibrosis: Pathological extracellular matrix deposition and tissue scarring in the vitreous or retina, shifting the tissue phenotype from active vascular leakage to permanent scarring.

These systemic stress pathways are conveyed to ocular target structures through specialized molecular chemical messengers: fat-derived adipokines and liver-derived hepatokines.

4. Molecular Messengers: The Roles of Adipokines and Hepatokines

The metabolic status of distant fat and liver tissue is communicated to the eye via specialized circulating peptide hormones:

• Adipokines: Bioactive signaling proteins secreted primarily by white adipose tissue.
• Hepatokines: Signaling proteins synthesized and released predominantly by hepatocytes.

In states of metabolic dysfunction, altered secretion patterns of these messengers disrupt ocular homeostasis.

  +---------------------------+             +---------------------------+
  |      ADIPOSE TISSUE       |             |        HEPATOCYTES        |
  |     (Visceral Fat)        |             |       (MASLD Liver)       |
  +-------------+-------------+             +-------------+-------------+
                |                                         |
                | Secretes                                | Secretes
                v                                         v
  +---------------------------+             +---------------------------+
  |        ADIPOKINES         |             |        HEPATOKINES        |
  | • Adiponectin   • Leptin  |             | • Adropin    • Fetuin-A   |
  | • Lipocalin-2   • Resistin|             | • FGF-21     • RBP-4     |
  +-------------+-------------+             +-------------+-------------+
                |                                         |
                +--------------------+--------------------+
                                     |
                                     v
  +---------------------------------------------------------------------+
  |                     SIX CORE CELLULAR STRESSORS                     |
  | 1. Chronic Inflammation           4. Vascular Dysfunction / VEGF    |
  | 2. Oxidative Stress / ROS         5. Impaired Autophagy             |
  | 3. Insulin Resistance             6. Ocular Fibrosis & Scarring     |
  +----------------------------------+----------------------------------+
                                     |
                                     v
  +---------------------------------------------------------------------+
  |                     AGE-RELATED OCULAR DISEASES                     |
  | • Diabetic Retinopathy (DR)       • Cataract                        |
  | • Age-Related Macular Deg. (AMD)  • Glaucoma                        |
  +---------------------------------------------------------------------+

4.1 Key Adipokines in Eye Health

1. Adiponectin (APN):
   • Native Function: Enhances insulin sensitivity, reduces ROS, stimulates protective autophagy via AMPK signaling, and maintains photoreceptor docosahexaenoic acid (DHA) levels via AdipoR1/ELOVL2 pathways.
   • Pathological Role: Serum APN decreases in systemic obesity. However, APN levels become paradoxically elevated within intraocular fluids (aqueous and vitreous humor) during advanced ocular diseases like PDR and Proliferative Vitreoretinopathy (PVR). In these local ocular environments, APN regulates the "vascular-fibrotic switch," suppressing VEGF signaling while shifting the pathological response toward fibrotic tissue scarring.
2. Leptin:
   • Native Function: Circulates in proportion to total fat mass to regulate energy balance and promote the metabolic clearance of extracellular amyloid deposits.
   • Pathological Role: Serum leptin levels are significantly reduced in patients with AMD (with lower levels correlating with advanced disease). Conversely, elevated intraocular leptin in vitreous humor stimulates a pro-angiogenic vicious cycle by upregulating local VEGF production. In glaucoma, leptin exhibits neuroprotective potential by suppressing RGC apoptosis and excitotoxic damage.
3. Lipocalin-2 (LCN-2):
   • Pathological Role: Elevated in obesity, LCN-2 signaling via NF-κB/STAT-1 pathways promotes caspase-1-mediated pyroptosis (inflammatory cell death) in retinal endothelial cells. High intraocular LCN-2 levels correlate with persistent macular edema in wet AMD, DR progression, and poor visual recovery following anti-VEGF therapy in Retinal Vein Occlusion (RVO).
4. Resistin:
   • Pathological Role: Strongly linked to insulin resistance and microangiopathy severity in T2DM. Resistin upregulates VEGF receptor expression (VEGFR1 and VEGFR2) on vascular endothelial cells, intensifying microvascular disease.

4.2 Key Hepatokines in Eye Health

1. Adropin:
   • Native Function: A 76-amino acid peptide that maintains energy homeostasis and capillary endothelial integrity.
   • Pathological Role: Circulating and vitreous adropin levels are significantly reduced in patients with MASLD and T2DM. A progressive decline in adropin directly correlates with increasing DR severity (progressing from non-DR to NPDR to PDR), positioning adropin as a protective vascular biomarker.
2. Fetuin-A:
   • Pathological Role: Synthesized almost exclusively by hepatocytes, fetuin-A secretion rises sharply during liver steatosis and inflammation. High fetuin-A levels stimulate inflammatory cytokine secretion (IL-6, IL-8) and VEGF expression in retinal endothelial and perivascular cells. Environmental Synergy: Proteomic analyses of aqueous humor reveal that fetuin-A expression reaches its highest levels in patients with combined T2DM and a history of cigarette smoking, demonstrating a potent toxic synergy between metabolic disease and environmental toxins in driving cataracts and retinopathy.
3. Fibroblast Growth Factor-21 (FGF-21):
   • Native Function: A key metabolic regulator that enhances glucose clearance and lipid oxidation.
   • Pathological Role: Though circulating FGF-21 is elevated in MASLD as a compensatory response to liver stress, therapeutic administration of long-acting FGF-21 suppresses retinal neovascularization, prevents microvascular leakage, and protects photoreceptors via APN activation and NF-κB suppression independent of VEGF-A.
4. Retinol Binding Protein-4 (RBP-4):
   • Native Function: The primary transport protein delivering vitamin A (retinol) from the liver to the retina.
   • Pathological Role: Excessive RBP-4 levels associated with metabolic dysfunction provoke retinal neurodegeneration. Overexpressed RBP-4 activates retinal microglia and induces pro-inflammatory signaling via Toll-Like Receptor 4 (TLR4), causing RGC loss and accelerating dry AMD and DR.

Translating these molecular insights into bedside therapies has driven the development of targeted drugs, metabolic surgical protocols, and active clinical monitoring strategies.

5. Therapeutic Implications, Lifestyle Modifications, and Clinical Cautions

Targeted Pharmacological Innovations Emerging pharmaceuticals seek to directly modulate dysregulated adipokine and hepatokine pathways to preserve visual function:

• AdipoRon: A small-molecule adiponectin receptor agonist. In glaucoma models, AdipoRon protects Retinal Ganglion Cells (RGCs) from oxidative apoptosis by upregulating mitochondrial transcription factors (PGC-1α, ERRα, TFAM). In DR models, it prevents microvascular apoptosis through the AdipoR1/AMPK/EGR4 signaling cascade.
• Fenretinide: An oral RBP-4 antagonist that lowers circulating RBP-4 levels. In clinical trials of patients with geographic atrophy (dry AMD), fenretinide reduced the accumulation of toxic retinal fluorophores and significantly lowered the incidence of secondary choroidal neovascularization.
• Long-acting FGF-21 Analogues: Engineered biopharmaceuticals that prevent microvascular breakdown in the retina by upregulating the inter-endothelial tight junction protein Claudin-1, effectively blocking retinal vascular leakage and inflammation.

Surgical and Lifestyle Interventions Systemic interventions that reverse underlying metabolic dysfunction produce direct structural improvements within the eye:

• Diet and Exercise: Targeted weight loss and regular physical activity reduce visceral fat volume, lowering circulating pro-inflammatory adipokines and preserving retinal capillary perfusion.
• Bariatric Surgery: Procedures such as laparoscopic sleeve gastrectomy and mini gastric bypass in patients with severe obesity demonstrate profound ocular benefits. Post-operative reduction in visceral fat correlates with significant reductions in Intraocular Pressure (IOP), increased retinal nerve fiber layer thickness, improved choroidal perfusion thickness (beneficial for AMD patients), and a reduced long-term risk of age-related cataract formation.

Clinical Cautions (The GLP-1 RA Paradox) While systemic metabolic management is vital for ocular health, clinicians must navigate a notable treatment paradox involving Glucagon-like peptide-1 receptor agonists (GLP-1RAs). Meta-analyses of randomized clinical trials indicate that initiating GLP-1RA therapy in patients with T2DM is associated with a paradoxical short-term increased risk of early-stage Diabetic Retinopathy worsening.

Physiological Mechanism: GLP-1RAs induce rapid glycemic lowering and metabolic adjustments. This sudden reduction in circulating glucose starves chronically adapted, hypoxic retinal capillaries, triggering transient microvascular ischemic stress and re-perfusion injury (a physiological response identical to the early DR worsening historically observed with rapid insulin intensification). Consequently, patients starting GLP-1RA therapy require baseline retinal examinations and ongoing surveillance.

  +-----------------------------------------------------------------------+
  |                       THE GLP-1 RA RETINAL PARADOX                    |
  +-----------------------------------+-----------------------------------+
                                      |
                                      v
  +-----------------------------------------------------------------------+
  |       Rapid Metabolic Adjustment & Glycemic Control via GLP-1RAs      |
  +-----------------------------------+-----------------------------------+
                                      |
                                      v
  +-----------------------------------------------------------------------+
  | Direct Microvascular Ischemic Stress & Transient Re-Perfusion Injury |
  +-----------------------------------+-----------------------------------+
                                      |
                                      v
  +-----------------------------------------------------------------------+
  |    Paradoxical Early Worsening of Retinopathy (Requires Surveillance) |
  +-----------------------------------------------------------------------+

Bridging molecular physiology with clinical practice provides a comprehensive blueprint for preserving visual function across the lifespan.

6. Summary & Key Takeaways for Students

Student "Cheat Sheet"

• Systemic-Ocular Axis: The eye is metabolically connected to distant organs; conditions like obesity and steatotic liver disease (MASLD) communicate directly with ocular tissues via vascular and biochemical pathways.
• Visceral Adiposity Over BMI: Total BMI fails to reflect fat distribution and ignores the "Obesity Paradox."Central adiposity indices (WtHR, BRI, CI, WWI) predict early AMD but not late AMD, with CI displaying a linear relationship and heavy alcohol consumption serving as a potent risk amplifier.
• Six Shared Stressors: Systemic metabolic disease damages ocular target tissues through chronic inflammation, oxidative stress (ROS), insulin resistance, vascular dysfunction/VEGF release, impaired autophagy, and ocular fibrosis.
• Chemical Messengers: Fat-derived adipokines (APN, Leptin, LCN-2, Resistin) and liver-derived hepatokines(Adropin, Fetuin-A, FGF-21, RBP-4) serve as key signaling molecules that exacerbate or protect against age-related eye diseases.
• Emerging Treatments & Cautions: Novel therapies target these molecular messengers directly (AdipoRon, Fenretinide, FGF-21), while metabolic bariatric surgery lowers intraocular pressure. However, rapid glucose lowering via GLP-1RAs requires vigilant retinal monitoring due to temporary microvascular re-perfusion stress.

Final Conceptual Synthesis

The future of vision preservation relies on a holistic, system-wide approach to human physiology. Rather than treating age-related ocular conditions solely as localized failures of the eye, modern medical science increasingly targets the underlying metabolic health of the patient. By managing visceral adiposity, supporting liver health, and modulating the chemical messengers circulating between our organs, we can open novel non-invasive frontiers in preventing global visual impairment and preserving sight throughout aging.

 

Frequently Asked Questions (FAQs)

How do adipokines and hepatokines mediate the link between metabolic health and eye diseases?

Adipokines (peptides secreted primarily by adipose tissue) and hepatokines (peptides secreted primarily by the liver) serve as vital endocrine messengers that mediate the cross-talk between systemic metabolic health—such as obesity and metabolic dysfunction-associated steatotic liver disease (MASLD)—and age-related ocular disorders.

Altered secretion patterns of these signaling molecules disrupt intraocular homeostasis, driving pathological processes across six primary pathways: chronic inflammation, oxidative stress, insulin resistance, microvascular dysfunction, impaired autophagy, and tissue fibrosis.

---

1. Adipokine Signaling Pathways (Fat–Eye Axis)

Adipose tissue dysfunction leads to dysregulated secretion of key adipokines, which enter systemic circulation and ocular fluids to influence retinal, choroidal, and optic nerve physiology:

• Adiponectin (APN):
  • Normal Function: Promotes insulin sensitivity, enhances glucose/lipid metabolism, and exerts anti-inflammatory protection via AdipoR1 and AdipoR2 receptors expressed in the retina.
  • Ocular Mediation: Retinal AdipoR1 signaling induces ELOVL2, an essential enzyme for supplying docosahexaenoic acid (DHA) needed for photoreceptor survival, and facilitates cholesterol removal. In diabetic retinopathy (DR) and proliferative DR (PDR), intraocular (aqueous and vitreous humor) APN levels rise as a protective, compensatory mechanism to increase nitric oxide production, enhance insulin sensitivity, and counteract VEGF-driven vascular damage. Genetic variations in AdipoR1 (rs10753929) and APN (rs822396) are strongly linked to advanced age-related macular degeneration (AMD).
• Leptin:
  • Normal Function: Secreted by white adipocytes in proportion to body fat mass to regulate energy balance.
  • Ocular Mediation: In early AMD, circulating leptin is often reduced; adequate leptin promotes the clearance of extracellular amyloid-beta and regulates lipid metabolism, preventing drusen accumulation beneath the retinal pigment epithelium (RPE). However, chronic local hyperleptinemia in the eye creates a pro-inflammatory and pro-angiogenic vicious cycle with vascular endothelial growth factor (VEGF), fueling choroidal neovascularization in wet AMD and retinal neovascularization in PDR. In glaucoma, leptin may confer neuroprotection by mitigating retinal ganglion cell (RGC) apoptosis and oxidative stress.
• Lipocalin-2 (LCN-2):
  • Normal Function: Inflammatory mediator markedly elevated in obesity.
  • Ocular Mediation: Retinal LCN-2 is upregulated via NF-κB and STAT-1 co-activation. Elevated LCN-2 levels in aqueous humor and serum trigger caspase-1-mediated pyroptosis, recruit inflammatory cells, disrupt photoreceptors, and promote endothelial cell apoptosis in DR and neovascular AMD. High aqueous humor LCN-2 is also associated with reduced visual recovery following anti-VEGF therapy in retinal vein occlusion (RVO).
• Resistin:
  • Normal Function: Secreted by adipocytes and immune cells; elevated in obesity and type 2 diabetes.
  • Ocular Mediation: Resistin upregulates VEGFR1 and VEGFR2 expression on vascular endothelial cells, exacerbating systemic insulin resistance and showing a strong positive correlation with microangiopathy severity and DR progression.

---

2. Hepatokine Signaling Pathways (Liver–Eye Axis)

Metabolic liver diseases like MASLD alter the secretion of liver-derived peptides, establishing a direct functional axis between liver health and retinal degeneration:

• Adropin:
  • Normal Function: Regulates energy homeostasis and endothelial health; circulating levels decrease in MASLD and type 2 diabetes.
  • Ocular Mediation: Serum and vitreous humor adropin concentrations display a progressive decline as diabetic retinopathy advances, reflecting a loss of protective microvascular endothelial signaling.
• Fetuin-A:
  • Normal Function: Secreted almost exclusively by hepatocytes; levels increase in hepatic steatosis, metabolic syndrome, and systemic inflammation.
  • Ocular Mediation: Circulating, vitreous, and aqueous humor fetuin-A levels are elevated in DR, wet AMD, and cataracts. Fetuin-A directly stimulates perivascular fat and endothelial cells to synthesize pro-inflammatory cytokines (IL-6, IL-8) and VEGF, driving blood-retinal barrier breakdown.
• Fibroblast Growth Factor-21 (FGF-21):
  • Normal Function: Master metabolic regulator of glucose and lipid utilization.
  • Ocular Mediation: Serum FGF-21 levels rise in response to hepatic steatosis and DR. Exogenous or therapeutic FGF-21 administration suppresses retinal neovascularization and vascular leakage by increasing adiponectin expression, upregulating the tight-junction protein Claudin-1, and inhibiting NF-κB and complement activation independently of VEGF-A.
• Retinol Binding Protein-4 (RBP-4):
  • Normal Function: Liver-derived transport protein that delivers vitamin A (retinol) to the retina.
  • Ocular Mediation: Elevated in MASLD, obesity, and diabetic retinopathy (both non-proliferative and proliferative). Abnormally elevated RBP-4 induces retinal neurodegeneration—causing microglial activation and loss of RGCs and bipolar cells—via a retinol-independent, Toll-like receptor 4 (TLR4)pro-inflammatory pathway.

---

3. Core Mediating Pathophysiological Mechanisms

The altered secretion of these adipokines and hepatokines converges on the eye through six central biological mechanisms:

1. Systemic and Local Inflammation: Upregulation of pro-inflammatory cascades (e.g., NF-κB, IL-6, TNF-α) by LCN-2, Fetuin-A, and Resistin.
2. Oxidative Stress: Leptin, excess RBP-4, and reduced adropin diminish local antioxidant defenses, increasing reactive oxygen species (ROS) and damaging photoreceptors and trabecular meshwork cells.
3. Insulin Resistance: Dysregulated adipokines alter insulin signaling in retinal microvessels and neural cells.
4. Vascular Dysfunction & Angiogenesis: Leptin, Resistin, and Fetuin-A promote VEGF secretion and endothelial leakage, whereas APN and FGF-21 maintain vascular integrity.
5. Impaired Autophagy & Lysosomal Stress: Metabolic stress impairs cellular recycling in the retinal pigment epithelium (RPE).
6. Fibrosis: Chronic intraocular inflammation drives subretinal fibrosis and tissue remodeling.

---

4. Emerging Therapeutic Implications

Targeting these metabolic endocrine pathways offers novel treatment options beyond traditional anti-VEGF injections:

• AdipoRon: An adiponectin receptor agonist that activates AMPK/PGC-1α signaling, protecting retinal ganglion cells from oxidative stress and cell death in glaucoma and DR models.
• FGF-21 Agonists: Recombinant FGF-21 or receptor agonists strengthen endothelial tight junctions (Claudin-1) and halt pathological neovascularization in AMD and DR.
• RBP-4 Antagonists (e.g., Fenretinide): Small-molecule antagonists designed to block toxic RBP-4-mediated TLR4 neuroinflammatory activation, currently under investigation for dry AMD.

 

What are the associations between body fat distribution indices and age-related macular degeneration?subdirectory